Technical Analysis for GALT - Galectin Therapeutics Inc.

Grade Last Price % Change Price Change
grade D 5.04 7.23% 0.34
GALT closed up 7.23 percent on Monday, March 18, 2019, on 1.26 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Earnings due: Mar 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical GALT trend table...

Date Alert Name Type % Chg
Mar 18 20 DMA Resistance Bearish 0.00%
Mar 18 Crossed Above 50 DMA Bullish 0.00%
Mar 18 Wide Bands Range Expansion 0.00%
Mar 18 Up 3 Days in a Row Strength 0.00%
Mar 15 NR7 Range Contraction 7.23%
Mar 15 Wide Bands Range Expansion 7.23%
Mar 15 Oversold Stochastic Weakness 7.23%
Mar 14 Bullish Engulfing Bullish 7.69%
Mar 14 Stochastic Buy Signal Bullish 7.69%
Mar 14 Wide Bands Range Expansion 7.69%

Older signals for GALT ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Galectin Therapeutics Inc., a development stage company, engages in the development of therapies for cancer and fibrotic disease. Its lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trial in Europe as a combination therapy with a tumor vaccine in patients with advanced melanoma. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Cancer Tumor Hepatitis Therapies For Cancer Lectins Liver Fibrosis Europe Galectin Galectin 3 Non Alcoholic Fatty Liver Disease Steatohepatitis
Is GALT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.49
52 Week Low 3.1
Average Volume 336,421
200-Day Moving Average 5.224
50-Day Moving Average 4.836
20-Day Moving Average 5.114
10-Day Moving Average 4.745
Average True Range 0.3815
ADX 20.35
+DI 22.9819
-DI 23.656
Chandelier Exit (Long, 3 ATRs ) 4.9155
Chandelier Exit (Short, 3 ATRs ) 5.2865
Upper Bollinger Band 6.0144
Lower Bollinger Band 4.2136
Percent B (%b) 0.46
BandWidth 35.21314
MACD Line -0.0577
MACD Signal Line -0.0081
MACD Histogram -0.0496
Fundamentals Value
Market Cap 176.65 Million
Num Shares 35.1 Million
EPS -0.61
Price-to-Earnings (P/E) Ratio -8.26
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.77
Resistance 3 (R3) 5.74 5.47 5.65
Resistance 2 (R2) 5.47 5.28 5.48 5.61
Resistance 1 (R1) 5.25 5.17 5.36 5.28 5.57
Pivot Point 4.98 4.98 5.03 5.00 4.98
Support 1 (S1) 4.77 4.79 4.87 4.80 4.51
Support 2 (S2) 4.49 4.68 4.51 4.47
Support 3 (S3) 4.28 4.49 4.43
Support 4 (S4) 4.31